Page 274 - Read Online

Figure 7: Expression of chemokine and chemokine receptors
Figure 6: Expression of metastatic markers in control and treated cells

Figure 8: (a) Scratched Assay performed on control CAF after 24 h; (b) Scratched Assay performed on control CAF after 48 h; (c) Scratched Assay
performed on control CAF after 72 h; (d) Ch-Np-treated cells after 24 h; (e) Ch-Np-treated cells after 48 h; (f) Ch-Np-treated cells after 72 h
Molecular marker studies Differentiating markers in CAF and Ch-Np-
This study was undertaken to evaluate mRNA expression treated CAF
of pluripotency, differentiation, metastatic spread, Keratin18 and Vimentin were the two differentiating
and chemokine markers in CAF cells before and after markers studied in CAF- and Ch-Np- treated cells. Figure
treatment with Ch-Np by using specific primers as 5 shows prominent expression of Keratin18 and Vimentin.
described in Table 1. However, both these genes were down-regulated in Ch-
Np-treated cells.
Pluripotency markers in CAF and Ch-Np-
treated CAF Metastatic markers in CAF and Ch-Np-treated
CAF
Pluripotency of cells is defined as properties of stem cells VEGF, MMP1, and MMP9 were studied as metastatic
which allow cells to proliferate indefinitely. Oct4, Nanog, genes in CAF and Ch-Np-treated CAF. There was slight
and Sox2 are known as such markers. These markers down-regulation of VEGF and MMP1 genes in Ch-Np-
were studied in untreated and treated CAF cells. It was treated CAF. However, complete down-regulation of
shown that these CAF cells normally expressed Oct4, MMP9 was observed in Ch-Np-treated CAF [Figure 6].
Nanog, and Sox2, indicating their proliferative activity as Also studied was E-Cadherin, an adhesive molecule and
transformed cells. However, in the Ch-Np treated cells, actively involved in the EMT (define EMT) process. It
Oct4 and Sox2 genes were down regulated and Nanog was observed that there was complete-down regulation
remained unchanged, as shown in Figure 4. of E-Cadherin in CAF as well as in Ch-Np-treated CAF,
264
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ July 29, 2016 ¦